Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Assets Average: 2021-2025

Historic Assets Average for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $352.4 million.

  • Xeris Biopharma Holdings' Assets Average rose 7.97% to $352.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $352.4 million, marking a year-over-year increase of 7.97%. This contributed to the annual value of $322.8 million for FY2024, which is 3.22% down from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Assets Average stood at $352.4 million for Q3 2025, which was up 8.42% from $325.1 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Assets Average ranged from a high of $352.4 million in Q3 2025 and a low of $217.8 million during Q4 2021.
  • For the 3-year period, Xeris Biopharma Holdings' Assets Average averaged around $329.1 million, with its median value being $326.4 million (2024).
  • In the last 5 years, Xeris Biopharma Holdings' Assets Average surged by 48.65% in 2022 and then declined by 3.14% in 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Assets Average (Quarterly) stood at $217.8 million in 2021, then surged by 48.65% to $323.8 million in 2022, then grew by 0.44% to $325.2 million in 2023, then declined by 0.96% to $322.1 million in 2024, then increased by 7.97% to $352.4 million in 2025.
  • Its Assets Average was $352.4 million in Q3 2025, compared to $325.1 million in Q2 2025 and $319.3 million in Q1 2025.